1.FK506-binding proteins and neurodegenerative diseases.
Li-qin ZHAO ; Jun-hai XIAO ; Wei HUANG ; Song LI
Acta Pharmaceutica Sinica 2002;37(9):743-748
Animals
;
Brain
;
metabolism
;
Humans
;
Nerve Regeneration
;
drug effects
;
Neurodegenerative Diseases
;
metabolism
;
prevention & control
;
Neuroprotective Agents
;
metabolism
;
therapeutic use
;
Tacrolimus Binding Protein 1A
;
metabolism
;
Tacrolimus Binding Proteins
;
metabolism
;
therapeutic use
2.The specific and rapid labeling of cell surface proteins with recombinant FKBP-fused fluorescent proteins.
Xi ZHANG ; Yongqiang DENG ; Hao CHANG ; Chen JI ; Mingshu ZHANG ; Jianxin PENG ; Tao XU ; Pingyong XU
Protein & Cell 2014;5(10):800-803
Amino Acid Substitution
;
Exocytosis
;
HEK293 Cells
;
Humans
;
Luminescent Proteins
;
genetics
;
metabolism
;
Membrane Proteins
;
chemistry
;
metabolism
;
Microscopy, Confocal
;
Protein Binding
;
Recombinant Fusion Proteins
;
biosynthesis
;
chemistry
;
genetics
;
Sirolimus
;
analogs & derivatives
;
chemistry
;
metabolism
;
Tacrolimus Binding Proteins
;
chemistry
;
genetics
;
metabolism
3.Aspirin-induced Bcl-2 translocation and its phosphorylation in the nucleus trigger apoptosis in breast cancer cells.
Bo Hwa CHOI ; Goutam CHAKRABORTY ; Kwanghee BAEK ; Ho Sup YOON
Experimental & Molecular Medicine 2013;45(10):e47-
Here, we report that B-cell lymphoma 2 (Bcl-2) is a novel target molecule of aspirin in breast cancer cells. Aspirin influenced the formation of a complex by Bcl-2 and FKBP38 and induced the nuclear translocation of Bcl-2 and its phosphorylation. These events inhibited cancer cell proliferation and subsequently enhanced MCF-7 breast cancer cell apoptosis. Bcl-2 knockdown using small interfering RNA (siRNA) delayed apoptotic cell death, which correlated with increased proliferation following aspirin exposure. In contrast, Bcl-2 overexpression enhanced the onset of aspirin-induced apoptosis, which was also associated with a significant increase in Bcl-2 phosphorylation in the nucleus. Therefore, this study may provide novel insight into the molecular mechanism of aspirin, particularly its anticancer effects in Bcl-2- and estrogen receptor-positive breast cancer cells.
Active Transport, Cell Nucleus/drug effects
;
*Apoptosis
;
Aspirin/*pharmacology
;
Cell Nucleus/*metabolism
;
Humans
;
MCF-7 Cells
;
Phosphorylation
;
Protein Binding
;
Proto-Oncogene Proteins c-bcl-2/genetics/*metabolism
;
Tacrolimus Binding Proteins/metabolism
4.FKBP-12 Exhibits an Inhibitory Activity on Calcium Oxalate Crystal Growth in Vitro.
In Sook HAN ; Yasushi NAKAGAWA ; Jong Wook PARK ; Min Ho SUH ; Sung IL SUH ; Song Woo SHIN ; Su Yul AHN ; Byung Kil CHOE
Journal of Korean Medical Science 2002;17(1):41-48
Urolithiasis and calcium oxalate crystal deposition diseases are still significant medical problems. In the course of nephrocalcin cDNA cloning, we have identified FKBP-12 as an inhibitory molecule of calcium oxalate crystal growth. lambdagt 11 cDNA libraries were constructed from renal carcinoma tissues and screened for nephrocalcin cDNA clones using anti-nephrocalcin antibody as a probe. Clones expressing recombinant proteins, which appeared to be antigenically cross-reactive to nephrocalcin, were isolated and their DNA sequences and inhibitory activities on the calcium oxalate crystal growth were determined. One of the clone lambdagt 11 #31-1 had a partial fragment (80 bp) of FKBP-12 cDNA as an insert. Therefore, a full-length FKBP-12 cDNA was PCR-cloned from the lambdagt 11 renal carcinoma cDNA library and was subcloned into an expression vector. The resultant recombinant FKBP-12 exhibited an inhibitory activity on the calcium oxalate crystal growth (Kd=10(-7) M). Physiological effect of the extracellular FKBP-12 was investigated in terms of macrophage activation and proinflammatory cytokine gene induction. Extracellular FKBP-12 failed to activate macrophages even at high concentrations. FKBP-12 seems an anti-stone molecule for the oxalate crystal deposition disease and recurrent stone diseases.
Animals
;
Base Sequence
;
Calcium Oxalate/*antagonists & inhibitors
;
Carcinoma, Renal Cell
;
Crystallization
;
DNA, Complementary
;
Extracellular Space
;
Glycoproteins/genetics
;
Humans
;
Kidney Calculi/*prevention & control
;
Kidney Neoplasms
;
Male
;
Mice
;
Mice, Inbred ICR
;
Molecular Sequence Data
;
Recombinant Fusion Proteins/genetics/metabolism
;
Tacrolimus Binding Protein 1A/genetics/*metabolism